NutriBand (NTRB) Operating Leases (2019 - 2026)
NutriBand's (NTRB) quarterly Operating Leases came in at $48305.0 in Q1 2026, down 13.87% quarter-over-quarter from $56081.0 in Q4 2025.
NutriBand (NTRB) Operating Leases (2019 - 2026) Analysis & Trends
NutriBand has disclosed Operating Leases across 5 years of filings, most recently posting $48305.0 for Q1 2026.
- Operating Leases for Q1 2026 came in at $48305.0, changed N/A year-over-year; the trailing twelve-month figure through Jan 2026 was $48305.0 (changed N/A YoY), and the FY2026 annual result was $48305.0, changed N/A from the prior year.
- Operating Leases came in at $48305.0 for Q1 2026 at NutriBand, down from $56081.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $71112.0 in Q2 2025 to a low of $8863.0 in Q4 2023.
- The 3-year median for Operating Leases is $41291.0 (2023), against an average of $40731.0.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | NutriBand | 41.21 Mn | 36.63 Mn | 88,941.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 48,305.00 |
| Oct 31, 2025 | 56,081.00 |
| Jul 31, 2025 | 63,682.00 |
| Apr 30, 2025 | 71,112.00 |
| Oct 31, 2023 | 8,863.00 |
| Jul 31, 2023 | 17,529.00 |
| Apr 30, 2023 | 25,999.00 |
| Jan 31, 2023 | 34,277.00 |
| Jan 31, 2020 | 10,050.00 |
| Oct 31, 2019 | 14,906.00 |
| Jul 31, 2019 | 19,652.00 |
| Apr 30, 2019 | 5,082.00 |